Slide 1: AngioDynamics Fourth Quarter 2023 Earnings Presentation
ANGIODYNAMICS Fourth Quarter 2023 Earnings Presentation July 12, 2023 1
Slide 2: Forward-Looking Statement
2 Forward-Looking Statement Notice Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations,
Slide 3: Corporate Developments – Q4 and FY23
Corporate Developments – Q4 and FY23 3 Continued focused investment in our 3 key Med Tech platforms: Auryon, Thrombus Management & NanoKnife Q4 revenue growth of 4.7% Med Tech up 17.2%; Med Device up 0.3% $11.8 million in Auryon sales, growth of 22.0% YOY Mechanical Thrombectomy (AngioVac and AlphaV
Slide 4: FY24 Guidance
FY24 Guidance 4 Guidance* Revenue $328 - $333 million Gross Margin Med Tech Med Device 50.0% - 52.0% 63.0% – 65.0% 43.0% - 45.0% Adjusted EPS ($0.28) – ($0.34) * FY23 pro forma results excluding the divested assets were $306.3 million for revenue, 50.5% for gross margin and adjusted loss per share o
Slide 5: Q4 and FY23 Results (unaudited)
Q4 and FY23 Results (unaudited) $ in thousands (except per share data) Q4 FY23 Q4 FY22 Change FY23 FY22 Change Revenue $91,074 $86,998 4.7% $338,752 $316,219 7.1% Med Tech Med Device $26,494 $64,580 $22,611 $64,387 17.2% 0.3% $96,687 $242,065 $78,717 $237,502 22.8% 1.9% United States International $
Slide 6: Q4 and FY23 Results
Q4 and FY23 Results 6 Med Device Med Tech 22.8% growth 1.9% growth Full Year Revenue Growth FY22 FY23 Full Year Revenue Contribution FY22 FY23 Med Device Med Tech 17.2% growth 0.3% growth Q4 Revenue Growth Q4 FY22 Q4 FY23 Q4 Revenue Contribution Q4 FY22 Q4 FY23 Med Tech Gross Margin 64.1% Med Device
Slide 7: Sales Comparison to Prior-Year Periods
Sales Comparison to Prior-Year Periods 7 Med Tech Q4 FY23 FY23 Auryon 22.0% 41.2% Thrombus Management* AngioVac AlphaVac** 7.8% (8.3%) 86.9% 8.9% (8.2%) 232.2% NanoKnife® Disposables 28.0% 27.1% NanoKnife® Capital 13.0% (9.4%) Med Device Q4 FY23 FY23 Core Peripheral 2.5% 7.9% Venous (6.4%) (12.4%) P
Slide 8: GAAP to Non-GAAP Reconciliation
GAAP to Non-GAAP Reconciliation 8
Slide 9: Reconciliation of GAAP to Non-GAAP Adjusted Net Income (Loss) and EPS
Reconciliation of GAAP to Non-GAAP Adjusted Net Income (Loss) and EPS Reconciliation of Net Loss to Adjusted EBITDA Includes costs related to merger and acquisition activities, restructurings, and unusual items, including asset impairments and write-offs, certain litigation, and other items. Adjustm
Slide 10: Reconciliation of GAAP to Non-GAAP Pro Forma FY23 Results
10 Reconciliation of GAAP to Non-GAAP Pro Forma FY23 Results Reconciliation of GAAP to Non-GAAP Pro Forma Adjusted Net Loss and EPS (in thousands, except per share data) (in thousands, except per share data)